LAMP2 and acute myeloid leukemia: Myelodysplastic syndrome (MDS) AML patients exhibit resistance to azacytidine and poor survival as a result of a significant defect in CMA caused by a lack of LAMP2 expression, and lysosomal autophagy inhibitors such as CQ can be effective on AML cells lacking LAMP2 [62].